In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study;Solunum yolu enfeksi̇yonu etkenleri̇ Streptococcus pneumoniae ve Streptococcus pyogenes'i̇n teli̇tromi̇si̇n ve 11 anti̇mi̇krobi̇k i̇laca i̇n vi̇tro duyarliliǧi: E-BASKETT-II sürveyans çalişmasinin türki̇ye sonuçlari

Mikrobiyoloji Bulteni

Volumn 41, Issue 1, 2007, Pages 1-9

  Gür, Deniz ^a   Mülazimoǧlu, Lütfiye ^b,n   Ünal, Serhat ^a   Balik, I ^c   Azap, A ^c   Ozturk R ^d   Yilmaz, M ^d   Yaman, A ^e   Saltoglu N ^e   Ayaz, C ^f   Cakir N ^g   Yuce A ^g   Ozinel Ma ^h   Sumerkan B ⁱ   Arslan, H ^j   Arman, D ^j   Zarakolu, P ^a   Ersoy, Y ^d   Firat, M ^d   Eraksoy, H ^k   Cagatay A ^k   Koksal I ^l   Caylan R ^l   Vahaboglu H ^m   Willke, A ^m   Korten, V ⁿ   Leblebicioglu H ^o   Gunaydin M ^o   Usluer, G ^p   Ozgunes I ^p   Gedikoglu S ^q   Ozakin C ^q   more..

^a HACETTEPE UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d Ankara Üni ^*

^e CUKUROVA UNIVERSITY   (Turkey)

^f DICLE UNIVERSITY   (Turkey)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h EGE UNIVERSITY   (Turkey)

ⁱ ERCIYES UNIVERSITY   (Turkey)

^j GAZI UNIVERSITY   (Turkey)

^k ISTANBUL UNIVERSITY   (Turkey)

^l KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^m KOCAELI UNIVERSITY   (Turkey)

ⁿ MARMARA UNIVERSITY   (Turkey)

^o ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^p ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^q ULUDAG UNIVERSITY   (Turkey)

more..

Author keywords

Antimicrobial resistance; Respiratory isolates; Streptococcus pneumoniae; Streptococcus pyogenes; Telithromycin

Indexed keywords

ANTIINFECTIVE AGENT; KETOLIDE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; KETOLIDES; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TURKEY;

EID: 34748902444     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg N and the Alexander Project Group. The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
2. Baquero F, Barrett JF, Courvalin P, Morrissey I, Piddock L, Novick WJ. Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clin Microbiol Infect 1998; 4 (Suppl 2): S19-26.
3. Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K. PROTEKT 1999-2000: A multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan. Int J Infect Dis 2005; 9: 27-36.
4. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 (Suppl 1): 1-7.
5. Felmingham D, Feldman C, Hryniewicz W, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8 (Suppl.2): 12-42.
6. th Informational Supplement. Approved Standard, M100-S14, 2004. NCCLS, Wayne, Pa.
7. Gür D, Güçiz B, Hasçelik G, et al. Streptococcus pneumoniae penicillin resistance in Turkey. J Chemother 2001; 13: 541-5.
8. Eşel D, Sümerkan B, Kocagöz S. Epidemiology of penicillin resistance in Streptococcus pneumoniae isolates in Kayseri, Turkey. Clin Microbiol Infect 2001; 7: 548-52.
9. Özakin C, Yilmaz E, Heper Y, Akalin H, Gedikoǧlu S. Penicillin resistance in Steptococcus pneumoniae. Clin Microbiol Infect 2001; 7 (Suppl 1) P893.
10. Küçükbasmaci Ö, Gönüllü N, Aktaş Z, Gürol D, Berkiten R. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int J Antimicrob Agents 2003; 22: 497-501.
11. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001; 48 (Suppl T1): 9-23.
12. Bryskier A. Ketolides telithromisin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000; 6: 661-9.
13. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) the first ketolide. J Antimicrob Chemother 2003; 51: 497-511.
14. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 2003; 51: 947-55.
15. Walsh F, Carnegy F, Willcock J, Amyes S. Comparative in vitro activity of telitromisin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 2004; 53: 793-6.
16. Leclerq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 2727-34.
17. Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005; 40: 1657-64.
18. Amsden GW. Pneumococcal macrolide resistance- Myth or reality? J Antimicrob Chemother 1999; 44: 1-6.
19. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395-401.
20. th European Congress of Clinical Microbiology and Infectious Diseases, May 10-13, 2003, Glasgow, UK. Poster no: 1544.
21. Şener B, Köseoǧlu Ö, Gür D, Bryskier A. Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey. J Chemother 2005; 17: 31-5.
22. Gür D, Özalp M, Sümerkan B, et al. Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: Results of a multicentre study in Turkey. Int J Antimicrob Agents 2002; 19: 207-11.
23. Çiftçi E, Dogru U, Güriz H, Aysev D, Ince E. Investigation of risk factors for tonsillopharyngitis with macrolide resistant Streptococcus pyogenes in Turkish children. Pediatr Int 2002; 44: 647-51.
24. Akata F, Özturk D, Tansel O, et al. Resistance to macrolides in group A streptococci from the European Section of Turkey: genetic and phenotypic characterization. Int J Antimicrob Agents 2002; 20: 461-3.
25. Açikgöz ZC, Göçer S, Tuncer S. Macrolide resistance determinants of group A streptococci in Ankara, Turkey. J Antimicrob Chemother 2003; 52: 110-2.
26. Cantón R, Mazzariol A, Morosini MI, Baquero F, Cornaglia G. Telithromycin activity is reduced by efflux in Streptococcus pyogenes. J Antimicrob Chemother 2005; 55: 489-95.
27. Poehlsgaard J, Douthwaite S. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr Opin Invest Drugs 2003; 4: 140-8.
28. Champney WS. Bacterial ribosomal subunit synthesis: a novel antibiotic target. Curr Drug Targets Infect Disord 2001; 1:19-36.
29. Goldstein F, Vidal B, Kitzis D. Telithromycin-resistant Streptococcus pneumoniae. Emerg Infect Dis 2005; 11: 1489-90.
30. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10-6.
31. Farrell DJ, Felmingham D. The PROTEKT Global Study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 2005; 56: 795-7.